Abstract

This study reportedly explored the emerging prospects of pharmacogenomics and personalized medicine within low-resource health systems, with a focus on Nigerian healthcare contexts. The central aim was to evaluate how genotype-guided therapy could enhance patient safety, optimize therapeutic efficacy, and inform rational drug prescribing despite infrastructural and resource constraints. A mixed-methods approach was reportedly employed, integrating simulated quantitative data for 500 patients with chronic diseases and hypothetical survey responses from clinicians and patients to examine perceptions, readiness, and adoption dynamics. The results reportedly indicated that pharmacogenomic-guided therapy reduced adverse drug reaction rates from 19% to 10.4%, increased mean therapeutic response scores from 72.5 to 81.3, and improved clinician confidence in prescribing. Patient willingness to undergo genetic testing was positively correlated with perceived benefits (r = 0.72, p < 0.001), while privacy concerns moderated engagement. The study reportedly concluded that even within constrained environments, strategic integration of pharmacogenomics could significantly improve clinical outcomes, provided that training, infrastructure, ethical safeguards, and culturally sensitive education were implemented. These findings were interpreted to have significant implications for policy, healthcare delivery, and resource allocation in low-resource settings, highlighting the feasibility and transformative potential of personalized medicine.